Condition 1: Malignant cancer with solid tumor. Condition 2: Malignant cancer with solid tumor. Condition 3: Malignant cancer with solid tumor. Condition 4: Malignant cancer with solid tumor. Condition 5: Malignant cancer with solid tumor. Condition 6: Malignant cancer with solid tumor. Condition 7: Malignant cancer with solid tumor. Condition 8: Malignant cancer with solid tumor. Condition 9: Malignant cancer with solid tumor. Condition 10: Malignant cancer with solid tumor. Malignant neoplasm
Conditions
Interventions
Intervention 1: Intervention group: Patients with solid malignant tumors who are candidated to get electrostatic therapy based on inclusion criteria. We use a flexible patch which is designed by nano
Sponsors
Iran Nano Fund
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who have different types of cancer with solid tumors. Patients who the biopsy of their tumors approved that the tumors are malignant. Patients who their malignant tumors are not obey the normal cellular pathways of the tissue. Patients with malignant tumors and highest levels of invasion are more appropriate for receiving treatment (i.e. triple negative breast cancer). Patients who their tumors are not too deep and not too far from the surface of the body. Pathological or radiological evidence of malignancy Pathological or radiological evidence of progression of the disease despite classical treatments Pathological or radiological evidence of recurrence of the disease despite classical treatments At least 3 months life expectency Patients with end-stage cancer who oncologists confirm that they did not profit from an alternative treatment, can include the study as a palliative therapy.
Exclusion criteria
Exclusion criteria: Patients who do not have appropriate general condition and need intensive care. Patients with tumors which tumor cells are obey the normal cellular pathways of the tissue. Patients who have different types of cancer which have no solid tumors. Patients with benign tumors or the types of malignant tumors which are not invasive enough. Patients who their tumors are deep and far from the surface of the skin. Coagulation disorders (INR>1.5) Pregnancy Platelets<150000 Neutropenia (neutrophil<1500) Anemia (Hemoglobin<12) Acute Infection Patients with pacemaker or any types of cardiac arrhythmia Abnormal biochemistry or electrolyte of the serum.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor sizes, Serum Tumor Marker, Clinical Manifestation , Pathological and microscopical features, Immunohistochemistry markers. In patients with end-stage cancer, their clinical and quality of life changes are investigated and the electrostatic therapy are considered as a palliative therapy. Timepoint: 12 days. Method of measurement: Imaging modalities, Blood Test, Investigating of Clinical Manifestation, Immunohistochemistry, pathological and microscopical markers and cellular staining. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality Of Life. Timepoint: 90 days. Method of measurement: Questionnaire about quality of life indicators based on EORTC QLQ-C30. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mohammad Abdolahad
Tehran University of Medical Sciences
Outcome results
None listed